UroPhenol is obtained by extracting the proanthocyanidins (PACs) found in cranberries (Vaccinium macrocarpon Aiton). Once extracted, the molecules are concentrated and standardized using a process developed by Nutra Canada to preserve their biological components. UroPhenol consists mainly of polymeric A-type PACs, whereas other berries contain B-type PACs. These A-type PACs are responsible for UroPhenol’s anti-adhesion properties by inhibiting pathogenic bacteria from binding to the bladder walls and causing infection.
Studies on UroPhenol and other cranberry products such as powders made from fruit and atomized juice concentrate have shown that this anti-adhesion property is directly related to the concentration level of A-type PACs. Tests have also shown that 15% UroPhenol is 125 times more effective at inhibiting the adhesion of E.coli bacteria than powders made from cranberries or cranberry juice concentrate. To measure this anti-adhesion activity, Nutra Canada uses a test developed by Dr. Amy Howell of Rutgers University in New Jersey. According to clinical studies on humans, a dose of 36 mg of PACs using the BL-DMAC method is the daily requirement to prevent UTIs. This dose is contained in 252 mg of 15% UroPhenol.
Nutra Canada recently began a study on humans to evaluate the efficacy of UroPhenol in preventing UTIs in young, sexually active women who are more prone to developing recurrent UTIs. This test conducted at the Institute of Nutrition and Functional Foods (INAF) is slated for completion in early 2015.
UroPhenol comes in a variety of PAC concentrations using the BL-DMAC method.
- UroPhenol Advantage standardized to 1% PACs (3.6 grams powder = 36 mg PACs)
- UroPhenol Select standardized to 5% PACs (720 mg powder = 36 mg PACs)
- UroPhenol Pure standardized to 15% PACs (252 mg powder = 36 mg PACs)